|
1
|
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance.
|
Am J Physiol Heart Circ Physiol
|
2006
|
3.78
|
|
2
|
Myostatin activation in patients with advanced heart failure and after mechanical unloading.
|
Eur J Heart Fail
|
2010
|
2.40
|
|
3
|
Systemic administration of L-arginine benefits mdx skeletal muscle function.
|
Muscle Nerve
|
2005
|
1.43
|
|
4
|
Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia.
|
J Thorac Cardiovasc Surg
|
2004
|
1.19
|
|
5
|
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.
|
PLoS One
|
2010
|
1.10
|
|
6
|
Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure.
|
Circulation
|
2002
|
1.08
|
|
7
|
Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain.
|
J Thorac Cardiovasc Surg
|
2003
|
1.05
|
|
8
|
Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure.
|
J Card Surg
|
2005
|
1.04
|
|
9
|
Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.
|
Muscle Nerve
|
2010
|
1.03
|
|
10
|
Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques.
|
Hum Gene Ther
|
2011
|
0.99
|
|
11
|
Molecular analysis of vector genome structures after liver transduction by conventional and self-complementary adeno-associated viral serotype vectors in murine and nonhuman primate models.
|
Hum Gene Ther
|
2010
|
0.99
|
|
12
|
Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy.
|
Circulation
|
2004
|
0.95
|
|
13
|
Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure.
|
Circulation
|
2003
|
0.94
|
|
14
|
Local myocardial overexpression of growth hormone attenuates postinfarction remodeling and preserves cardiac function.
|
Ann Thorac Surg
|
2004
|
0.87
|
|
15
|
Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus.
|
Curr Protoc Microbiol
|
2013
|
0.85
|
|
16
|
Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling.
|
J Heart Lung Transplant
|
2004
|
0.83
|
|
17
|
Enhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression.
|
Hum Gene Ther Methods
|
2013
|
0.82
|
|
18
|
Gene therapy in large animal models of human cardiovascular genetic disease.
|
ILAR J
|
2009
|
0.82
|
|
19
|
Targeted overexpression of growth hormone by adenoviral gene transfer preserves myocardial function and ventricular geometry in ischemic cardiomyopathy.
|
J Mol Cell Cardiol
|
2004
|
0.80
|
|
20
|
Status of therapeutic gene transfer to treat cardiovascular disease in dogs and cats.
|
J Vet Cardiol
|
2011
|
0.76
|
|
21
|
Sarcomeric-alpha-actinin defective in vinculin-binding causes Z-line expansion and nemaline-like body formation in cultured chick myotubes.
|
Exp Cell Res
|
2009
|
0.75
|
|
22
|
Status of therapeutic gene transfer to treat canine dilated cardiomyopathy in dogs.
|
Vet Clin North Am Small Anim Pract
|
2010
|
0.75
|